Immune Design Corporation Announces Treatment Of First Patient In Phase 1 Clinical Trial Of ID-G305 Cancer Immunotherapy Agent
2/27/2014 9:25:31 AM
SEATTLE and SAN FRANCISCO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Immune Design, a clinical-stage immunotherapy company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced treatment of the first patient in a Phase 1 clinical trial of ID-G305, a cancer immunotherapy investigational agent from the company's GLAASTM platform.
Help employers find you! Check out all the jobs and post your resume.